ClinicalTrials.gg
CompletedNCT03714022Updated Jan 7, 2021Results posted

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

A Phase 1 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
27th of 63
140 · median 119
Started
2018
with 3 others
Phase 1
8 of 63
none open now
Registered
52nd of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 27th largest by enrollment, is one of 4 that started in 2018, is one of 8 in phase 1, and was the 52nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The main objective of this study is to compare the pharmacokinetics (PK) of the abatacept drug product converted from drug substance by a new drug substance process (Treatment A) relative to the current drug substance process (Treatment B) following a single dose (750 mg) intravenous (IV) infusion in healthy participants.

Read the detailed description

Participants will be admitted to the clinical facility the day prior to dosing (Day -1) and will be confined until at least 24 hours post-dose. On Day 1, eligible participants will be randomized in a 1:1 ratio to either Treatment A or Treatment B. The randomization will be stratified by weight categories: >= 60 to \< 70 kg, >= 70 to \< 80 kg, >= 80 to \< 90 kg, and >= 90 to \<= 100 kg.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight will be between 60 and 100 kg, inclusive.
  • Women of (WOCBP) must have a negative serum pregnancy test within 24 hours prior to the start of study treatment.
  • Women must not be breastfeeding.
  • WOCBP must agree to follow instructions for method(s) of for the duration of treatment with abatacept plus 5 half-lives of abatacept (85 days) plus 30 days (duration of ovulatory cycle) for a total of 115 days post-treatment completion.
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with abatacept plus 5 half-lives of abatacept (85 days) plus the duration of spermatogenesis (90 days) for a total of 175 days after the last dose of study treatment. In addition, male participants must be willing to refrain from sperm donation during this time.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a present or previous malignancy within the last 5 years prior to screening (except documented history of cured non- squamous or basal cell skin carcinoma or cervical carcinoma in situ). Participants who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
  • Participants with a history of herpes zoster.
  • Donation of blood to a blood bank or in a clinical study (except a screening visit or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks of study treatment administration for plasma only).
  • Blood transfusion within 4 weeks of study treatment administration.
  • Recent (within 6 months of study treatment administration) history of smoking or current smokers. This includes participants using electronic cigarettes or nicotine-containing products such as tobacco for chewing, nicotine patches, nicotine lozenges, or nicotine gum.
  • History of allergy to abatacept or related compounds.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.

    Drug: Abatacept

  • Active comparator
    Treatment B

    Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.

    Drug: Abatacept

Interventions

  • Participants will receive abatacept at a single dose 750 mg as IV infusion.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    Maximum Observed Serum Concentration

    Time frame: From drug administration to 70 days following drug administration

  2. Area Under the Curve AUC(INF)

    Area under the serum concentration-time curve from time zero extrapolated to infinity

    Time frame: From drug administration to 70 days following drug administration

Secondary outcomes

  1. Time of Maximum Observed Serum Concentration (Tmax)

    Time of maximum observed serum concentration

    Time frame: From drug administration to 70 days following drug administration

  2. Area Under the Curve AUC(0-T)

    Area under the serum concentration-time curve from zero to the last time of the last quantifiable concentration

    Time frame: From drug administration to 70 days following drug administration

  3. Area Under the Curve AUC(0-28)

    Area under the serum concentration-time curve from time zero to 28 days after dosing

    Time frame: From drug administration to 70 days following drug administration

  4. Total Body Clearance (CLT)

    Total body clearance

    Time frame: From drug administration to 70 days following drug administration

  5. Volume of Distribution at Steady-State (Vss)

    Volume of distribution at steady-state

    Time frame: From drug administration to 70 days following drug administration

  6. Terminal Phase Elimination Half-life (T-HALF)

    Terminal phase elimination half-life in serum

    Time frame: From drug administration to 70 days following drug administration

  7. Number of Participants Experiencing Positive Immunogenicity Response to Abatacept

    Positive immunogenicity response to Abatacept was defined if one of the following criteria was met: 1. missing baseline immunogenicity measurement and a positive, post-baseline, laboratory-reported immunogenicity response; 2. a negative laboratory-reported baseline immunogenicity response and a positive, post-baseline, laboratory-reported response; 3. a positive, laboratory-reported, baseline immunogenicity response and a positive, post-baseline, laboratory-reported immunogenicity response with a titer value greater than the baseline titer value.

    Time frame: From Day 1 (Predose) to Day 71 (Study Discharge), assessed at day 1, day 29, day 57 and day 71

  8. Number of Participants Experiencing Adverse Events

    Number of participants experiencing different types of Adverse Events (AEs). Peri-infusional AEs: occurring during the 30 minute study drug infusion period Post-infusional AEs: occurring within 24 hours post drug infusion

    Time frame: From drug administration to 56 days following drug administration

  9. Change From Baseline in Blood Pressure

    Mean Change from Baseline in systolic and diastolic blood pressure values

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  10. Change From Baseline in Heart Rate

    Mean Change from Baseline in heart rate values

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  11. Change From Baseline in Respiration Rate

    Mean Change from Baseline in respiration rate values

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  12. Change From Baseline in Body Temperature

    Mean Change from Baseline in body temperature values

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  13. Change From Baseline in Electrocardiogram (ECG) Parameters

    Mean Change from Baseline in ECG parameters, including PR interval, QRS interval, QT interval, and QTC Fridericia

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  14. Number of Participants Experiencing Clinically Significant Physical Examination Abnormalities

    Number of participants experiencing clinically significant physical examination abnormal findings

    Time frame: From the pre-treatment period to 70 days after start of study medication (approximately 100 days)

  15. Change From Baseline in Laboratory Test Results - Hematology 1

    Mean Change from Baseline in laboratory test results - Hematology parameters 1

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  16. Change From Baseline in Laboratory Test Results - Hematology 2

    Mean Change from Baseline in laboratory test results - Hematology parameters 2

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  17. Change From Baseline in Laboratory Test Results - Hematology 3

    Mean Change from Baseline in laboratory test results - Hematocrit

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  18. Change From Baseline in Laboratory Test Results - Chemistry 1

    Mean Change from Baseline in laboratory test results - Chemistry parameters 1

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  19. Change From Baseline in Laboratory Test Results - Chemistry 2

    Mean Change from Baseline in laboratory test results - Chemistry parameters 2

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  20. Change From Baseline in Laboratory Test Results - Chemistry 3

    Mean Change from Baseline in laboratory test results - Chemistry parameters 3

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

  21. Change From Baseline in Laboratory Test Results -Hematology and Chemistry 4

    Mean Change from Baseline in laboratory test results - hematology and chemistry parameters 4

    Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication

07

Results

Posted Jan 7, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort A (New Process)Cohort B (Current Process)
Started7070
Completed6667
Not completed43
Withdrew: Adverse event10
Withdrew: Consent withdrawal01
Withdrew: Lost to follow-up32

Outcome measures

PrimaryMaximum Observed Serum Concentration (Cmax)

Maximum Observed Serum Concentration

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Geometric mean · ug/mL
Maximum Observed Serum Concentration (Cmax)
ug/mLCohort A (New Process)Cohort B (Current Process)
Maximum Observed Serum Concentration (Cmax)237.0341 ± 26236.2882 ± 23
Statistical analysis
  • Cohort A (New Process) vs Cohort B (Current Process) · Ratio of geometric means: 0.998 · 90% CI 0.941 to 1.058Cohort A vs Cohort B
PrimaryArea Under the Curve AUC(INF)

Area under the serum concentration-time curve from time zero extrapolated to infinity

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Geometric mean · ug*h/mL
Area Under the Curve AUC(INF)
ug*h/mLCohort A (New Process)Cohort B (Current Process)
Area Under the Curve AUC(INF)35693.8 ± 2238254.6 ± 16
Statistical analysis
  • Cohort A (New Process) vs Cohort B (Current Process) · Ratio of geometric means: 0.929 · 90% CI 0.884 to 0.976Cohort A vs Cohort B
SecondaryTime of Maximum Observed Serum Concentration (Tmax)

Time of maximum observed serum concentration

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Median · Hours
Time of Maximum Observed Serum Concentration (Tmax)
HoursCohort A (New Process)Cohort B (Current Process)
Time of Maximum Observed Serum Concentration (Tmax)1.000 (0.47 to 24.00)1.000 (0.25 to 24.00)
SecondaryArea Under the Curve AUC(0-T)

Area under the serum concentration-time curve from zero to the last time of the last quantifiable concentration

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Geometric mean · ug*h/mL
Area Under the Curve AUC(0-T)
ug*h/mLCohort A (New Process)Cohort B (Current Process)
Area Under the Curve AUC(0-T)34473.2 ± 2236671.6 ± 16
Statistical analysis
  • Cohort A (New Process) vs Cohort B (Current Process) · Ratio of geometric means: 0.936 · 90% CI 0.891 to 0.983Cohort A vs Cohort B
SecondaryArea Under the Curve AUC(0-28)

Area under the serum concentration-time curve from time zero to 28 days after dosing

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Geometric mean · ug*h/mL
Area Under the Curve AUC(0-28)
ug*h/mLCohort A (New Process)Cohort B (Current Process)
Area Under the Curve AUC(0-28)28597.9 ± 2029765.7 ± 15
Statistical analysis
  • Cohort A (New Process) vs Cohort B (Current Process) · Ratio of geometric means: 0.957 · 90% CI 0.915 to 1.001Cohort A vs Cohort B
SecondaryTotal Body Clearance (CLT)

Total body clearance

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Geometric mean · mL/h/Kg
Total Body Clearance (CLT)
mL/h/KgCohort A (New Process)Cohort B (Current Process)
Total Body Clearance (CLT)0.2642 ± 210.2445 ± 17
SecondaryVolume of Distribution at Steady-State (Vss)

Volume of distribution at steady-state

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Geometric mean · L/Kg
Volume of Distribution at Steady-State (Vss)
L/KgCohort A (New Process)Cohort B (Current Process)
Volume of Distribution at Steady-State (Vss)0.10444 ± 210.10462 ± 21
SecondaryTerminal Phase Elimination Half-life (T-HALF)

Terminal phase elimination half-life in serum

Time frame:
From drug administration to 70 days following drug administration
Reported as:
Mean · Hours
Terminal Phase Elimination Half-life (T-HALF)
HoursCohort A (New Process)Cohort B (Current Process)
Terminal Phase Elimination Half-life (T-HALF)357.464 ± 78.6519369.425 ± 76.0162
SecondaryNumber of Participants Experiencing Positive Immunogenicity Response to Abatacept

Positive immunogenicity response to Abatacept was defined if one of the following criteria was met: 1. missing baseline immunogenicity measurement and a positive, post-baseline, laboratory-reported immunogenicity response; 2. a negative laboratory-reported baseline immunogenicity response and a positive, post-baseline, laboratory-reported response; 3. a positive, laboratory-reported, baseline immunogenicity response and a positive, post-baseline, laboratory-reported immunogenicity response with a titer value greater than the baseline titer value.

Time frame:
From Day 1 (Predose) to Day 71 (Study Discharge), assessed at day 1, day 29, day 57 and day 71
Reported as:
Count of participants · Participants
Number of Participants Experiencing Positive Immunogenicity Response to Abatacept
ParticipantsCohort A (New Process)Cohort B (Current Process)
Number of Participants Experiencing Positive Immunogenicity Response to Abatacept1411
SecondaryNumber of Participants Experiencing Adverse Events

Number of participants experiencing different types of Adverse Events (AEs). Peri-infusional AEs: occurring during the 30 minute study drug infusion period Post-infusional AEs: occurring within 24 hours post drug infusion

Time frame:
From drug administration to 56 days following drug administration
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events
ParticipantsCohort A (New Process)Cohort B (Current Process)
Participants with at least 1 Adverse Event2018
Participants with at least 1 peri-infusional Adverse Event12
Participants with at least 1 post-infusional Adverse Event43
Participants with Adverse Event related to study drug87
Death00
Serious Adverse Events (SAEs)00
Adverse Events leading to discontinuation00
SecondaryChange From Baseline in Blood Pressure

Mean Change from Baseline in systolic and diastolic blood pressure values

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · mmHg
Change From Baseline in Blood Pressure
mmHgCohort A (New Process)Cohort B (Current Process)
Systolic Blood Pressure-0.3 ± 12.212.0 ± 10.72
Diastolic Blood Pressure-0.8 ± 7.69-0.7 ± 8.52
SecondaryChange From Baseline in Heart Rate

Mean Change from Baseline in heart rate values

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · bpm
Change From Baseline in Heart Rate
bpmCohort A (New Process)Cohort B (Current Process)
Change From Baseline in Heart Rate1.6 ± 9.990 ± 9.34
SecondaryChange From Baseline in Respiration Rate

Mean Change from Baseline in respiration rate values

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · breath/min
Change From Baseline in Respiration Rate
breath/minCohort A (New Process)Cohort B (Current Process)
Change From Baseline in Respiration Rate1.0 ± 3.270.5 ± 3.63
SecondaryChange From Baseline in Body Temperature

Mean Change from Baseline in body temperature values

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · C
Change From Baseline in Body Temperature
CCohort A (New Process)Cohort B (Current Process)
Change From Baseline in Body Temperature-0.01 ± 0.486-0.06 ± 0.392
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters

Mean Change from Baseline in ECG parameters, including PR interval, QRS interval, QT interval, and QTC Fridericia

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · msec
Change From Baseline in Electrocardiogram (ECG) Parameters
msecCohort A (New Process)Cohort B (Current Process)
PR Interval1.6 ± 17.66-1.8 ± 10.49
QRS Interval1.6 ± 5.70-0.0 ± 5.45
QT Interval-1.1 ± 22.53-2.1 ± 17.28
QTC Fridericia1.4 ± 13.200.5 ± 12.70
SecondaryNumber of Participants Experiencing Clinically Significant Physical Examination Abnormalities

Number of participants experiencing clinically significant physical examination abnormal findings

Time frame:
From the pre-treatment period to 70 days after start of study medication (approximately 100 days)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Clinically Significant Physical Examination Abnormalities
ParticipantsCohort A (New Process)Cohort B (Current Process)
Number of Participants Experiencing Clinically Significant Physical Examination Abnormalities00
SecondaryChange From Baseline in Laboratory Test Results - Hematology 1

Mean Change from Baseline in laboratory test results - Hematology parameters 1

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · x10*9 cells/L
Change From Baseline in Laboratory Test Results - Hematology 1
x10*9 cells/LCohort A (New Process)Cohort B (Current Process)
Platelet Count3.9 ± 30.99-1.6 ± 31.81
Basophils (absolute)-0.026 ± 0.0741-0.015 ± 0.0292
Eosinophils (absolute)-0.006 ± 0.10060.012 ± 0.012
Leukocytes0.09 ± 1.154-0.07 ± 1.225
Lymphocytes (absolute)0.073 ± 0.5086-0.028 ± 0.3162
Monocytes (absolute)-0.045 ± 0.1163-0.033 ± 0.1453
Neutrophils (absolute)0.083 ± 0.9523-0.011 ± 1.0654
SecondaryChange From Baseline in Laboratory Test Results - Hematology 2

Mean Change from Baseline in laboratory test results - Hematology parameters 2

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · Fraction
Change From Baseline in Laboratory Test Results - Hematology 2
FractionCohort A (New Process)Cohort B (Current Process)
Basophils (relative)-0.0034 ± 0.00779-0.0023 ± 0.00462
Eosinophils (relative)-0.0008 ± 0.017120.0024 ± 0.01372
Lymphocytes (relative)0.0107 ± 0.076090.0019 ± 0.06250
Monocytes (relative)-0.0073 ± 0.01389-0.0041 ± 0.02072
Neutrophils (relative)0.0008 ± 0.086090.0021 ± 0.07425
SecondaryChange From Baseline in Laboratory Test Results - Hematology 3

Mean Change from Baseline in laboratory test results - Hematocrit

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · Proportion of Blood Volume
Change From Baseline in Laboratory Test Results - Hematology 3
Proportion of Blood VolumeCohort A (New Process)Cohort B (Current Process)
Change From Baseline in Laboratory Test Results - Hematology 3-0.0017 ± 0.018450.0014 ± 0.01767
SecondaryChange From Baseline in Laboratory Test Results - Chemistry 1

Mean Change from Baseline in laboratory test results - Chemistry parameters 1

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · U/L
Change From Baseline in Laboratory Test Results - Chemistry 1
U/LCohort A (New Process)Cohort B (Current Process)
Alanine Aminotransferase (ALT)0.6 ± 9.01-1.3 ± 8.50
Alkaline Phosphatase (ALP)-3.0 ± 7.52-0.4 ± 8.86
Aspartate Aminotransferase (AST)1.1 ± 15.89-1.1 ± 4.11
Lactate Dehydrogenase (LD)1.4 ± 47.60-3.2 ± 18.30
SecondaryChange From Baseline in Laboratory Test Results - Chemistry 2

Mean Change from Baseline in laboratory test results - Chemistry parameters 2

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · umol/L
Change From Baseline in Laboratory Test Results - Chemistry 2
umol/LCohort A (New Process)Cohort B (Current Process)
Bilirubin, Direct-0.01 ± 0.804-0.09 ± 0.759
Bilirubin, Total-0.25 ± 3.467-0.54 ± 3.297
Creatinine-2.2 ± 9.72-1.5 ± 8.58
SecondaryChange From Baseline in Laboratory Test Results - Chemistry 3

Mean Change from Baseline in laboratory test results - Chemistry parameters 3

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · mmol/L
Change From Baseline in Laboratory Test Results - Chemistry 3
mmol/LCohort A (New Process)Cohort B (Current Process)
Blood Urea Nitrogen0.29 ± 1.2640.12 ± 1.125
Calcium, Total-0.027 ± 0.0809-0.012 ± 0.0787
Chloride, Serum0.4 ± 1.83-0.1 ± 2.01
Magnesium, Serum-0.011 ± 0.0610-0.015 ± 0.0666
Phosphorus, Inorganic-0.010 ± 0.1537-0.040 ± 0.1431
Potassium, Serum-0.13 ± 0.266-0.23 ± 0.311
Sodium, Serum-0.1 ± 2.22-0.2 ± 2.09
Glucose, Serum0.04 ± 0.5160.04 ± 0.383
Uric Acid0.006 ± 0.04250.004 ± 0.0341
SecondaryChange From Baseline in Laboratory Test Results -Hematology and Chemistry 4

Mean Change from Baseline in laboratory test results - hematology and chemistry parameters 4

Time frame:
From baseline (last result before start of study medication) to 70 days after start of study medication
Reported as:
Mean · g/L
Change From Baseline in Laboratory Test Results -Hematology and Chemistry 4
g/LCohort A (New Process)Cohort B (Current Process)
Hemoglobin (g/L)-0.6 ± 6.060.4 ± 5.57
Albumin (g/L)-0.9 ± 2.53-0.3 ± 2.39
Protein, Total (g/L)-1.2 ± 4.50-0.4 ± 4.32

Adverse events

Collected over From drug administration to 70 days following drug administration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (New Process)0/70 (0%)0/70 (0%)6/70 (8.6%)
Cohort B (Current Process)0/70 (0%)0/70 (0%)3/70 (4.3%)
Most frequent other events
Most frequent other events
EventCohort A (New Process)Cohort B (Current Process)
NasopharyngitisInfections and infestations6/703/70

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A (New Process)Cohort B (Current Process)Total
Mean36.4 ± 9.2936.6 ± 9.3736.5 ± 9.30
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (New Process)Cohort B (Current Process)Total
Female292655
Male414485
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A (New Process)Cohort B (Current Process)Total
Hispanic or Latino404484
Not Hispanic or Latino302656
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A (New Process)Cohort B (Current Process)Total
American Indian or Alaska Native112
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American222951
White453984
More than one race000
Unknown or Not Reported101
08

Study locations

2 sites
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • PPD Development, LP
    Austin, Texas 78744, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2019, 4 months.

Results were first posted in Jan 2021, 1 year 9 months after primary completion.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 4 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 22, 2018
StartActual
Nov 9, 2018
Primary completionActual
Apr 2, 2019
CompletionActual
Apr 2, 2019
Results first posted
Jan 7, 2021
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03714022
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Nov 9, 2018
Primary completion
Apr 2, 2019
Completion
Apr 2, 2019
Results posted
Jan 7, 2021
Last update
Jan 7, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion